176 related articles for article (PubMed ID: 23010687)
1. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease.
Sazuka S; Katsuno T; Nakagawa T; Saito M; Saito K; Matsumura T; Arai M; Sato T; Yokosuka O
Eur J Clin Nutr; 2012 Nov; 66(11):1219-23. PubMed ID: 23010687
[TBL] [Abstract][Full Text] [Related]
2. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn's disease.
Ono Y; Hirai F; Matsui T; Beppu T; Yano Y; Takatsu N; Takaki Y; Nagahama T; Hisabe T; Yao K; Higashi D; Futami K
Dig Endosc; 2012 Nov; 24(6):432-8. PubMed ID: 23078435
[TBL] [Abstract][Full Text] [Related]
3. [A comparative study of induction of remission and cost-effectiveness of enteral nutrition versus infliximab in moderate-to-severe Crohn's disease].
Zhu WM; Zuo LG; Li Y; Cao L; Zhang W; Gu YF; Xu M; Li N; Li JS
Zhonghua Nei Ke Za Zhi; 2013 Sep; 52(9):721-5. PubMed ID: 24314158
[TBL] [Abstract][Full Text] [Related]
4. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults.
Hirai F; Ishihara H; Yada S; Esaki M; Ohwan T; Nozaki R; Ashizuka S; Inatsu H; Ohi H; Aoyagi K; Mizuta Y; Matsumoto T; Matsui T
Dig Dis Sci; 2013 May; 58(5):1329-34. PubMed ID: 22926500
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
[TBL] [Abstract][Full Text] [Related]
7. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders.
Laharie D; Chanteloup E; Chabrun E; Subtil C; Kowo M; El Hanafi K; DE Lédinghen V
Aliment Pharmacol Ther; 2009 Jun; 29(12):1240-8. PubMed ID: 19416134
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to Infliximab in children with luminal Crohn's disease.
Grover Z; Biron R; Carman N; Lewindon P
J Crohns Colitis; 2014 Aug; 8(8):739-46. PubMed ID: 24445015
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
10. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
[TBL] [Abstract][Full Text] [Related]
11. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
[TBL] [Abstract][Full Text] [Related]
12. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy.
Matsumoto T; Iida M; Kohgo Y; Imamura A; Kusugami K; Nakano H; Fujiyama Y; Matsu T; Hibi T
Scand J Gastroenterol; 2005 Dec; 40(12):1423-30. PubMed ID: 16316890
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the loss of response to infliximab in patients with Crohn's disease.
Sono K; Yamada A; Yoshimatsu Y; Takada N; Suzuki Y
Cytokine; 2012 Aug; 59(2):410-6. PubMed ID: 22633084
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response.
Kamata N; Oshitani N; Watanabe K; Watanabe K; Hosomi S; Noguchi A; Yukawa T; Yamagami H; Shiba M; Tanigawa T; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
Dig Dis Sci; 2015 May; 60(5):1382-8. PubMed ID: 25532505
[TBL] [Abstract][Full Text] [Related]
17. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
[TBL] [Abstract][Full Text] [Related]
18. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab therapy in children with Crohn disease previously treated with infliximab.
Cozijnsen M; Duif V; Kokke F; Kindermann A; van Rheenen P; de Meij T; Schaart M; Damen G; Norbruis O; Pelleboer R; Van den Neucker A; van Wering H; Hummel T; Oudshoorn J; Escher J; de Ridder L;
J Pediatr Gastroenterol Nutr; 2015 Feb; 60(2):205-10. PubMed ID: 25286063
[TBL] [Abstract][Full Text] [Related]
20. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA
J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
